Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics


Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases

Read more from the original source:
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Related Posts